| DrugRepV_0006 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Zika virus | GZ01, a recent Asian lineage | NA | Plaque assay | Decrease (100 %) | Approved | 29033372 |
| DrugRepV_0337 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0352 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus | NA | Renilla luciferase assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0359 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0360 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0376 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0378 | Danazol | Genito Urinary System and Sex Hormones | Endometriosis and fibrocystic breast disease | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0390 | Hydroxyprogesterone Caproate | Genito Urinary System and Sex Hormones | Spontaneous preterm births | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26041706 |
| DrugRepV_0408 | Raloxifene Hydrochloride | Genito Urinary System and Sex Hormones | Osteoporosis | Corticosteroid-induced bone loss | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26041706 |
| DrugRepV_0428 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0446 | Terconazole | Genito Urinary System and Sex Hormones | Candidiasis (a yeast-like fungal infection) of the vulva and vagina | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0455 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0473 | Terconazole | Genito Urinary System and Sex Hormones | Candidiasis (a yeast-like fungal infection) of the vulva and vagina | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0484 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0503 | Terconazole | Genito Urinary System and Sex Hormones | Candidiasis (a yeast-like fungal infection) of the vulva and vagina | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0527 | Raloxifene/Evista | Genito Urinary System and Sex Hormones | Osteoporosis | Corticosteroid-induced bone loss | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26038505 |
| DrugRepV_0545 | Clomiphene | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0552 | Bazedoxifene | Genito Urinary System and Sex Hormones | Postmenopausal osteoporosis | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0581 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0582 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0585 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | EBOV/Kik | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0586 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | EBOV/May | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0587 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | SUDV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0588 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | MARV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0589 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | RAVV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0595 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | EBOV/Kik | NA | Real-time PCR | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0596 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | SUDV | NA | Real-time PCR | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0597 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | MARV | NA | Real-time PCR | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0601 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | ma-EBOV | NA | NA | Increase | Approved | 23785035 |
| DrugRepV_0603 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | VLP-GP | NA | Flow cytometry | Decrease (93 %) | Approved | 23785035 |
| DrugRepV_0617 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 23577127 |
| DrugRepV_0637 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Lassa virus | Josiah | NA | Real-time PCR | No significant effect | Approved | 23577127 |
| DrugRepV_0656 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (98 %) | Approved | 23577127 |
| DrugRepV_0680 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (93 %) | Approved | 23577127 |
| DrugRepV_0702 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Ebola virus | EBOLA-eGFP | NA | Fluorescence-based assay | No significant effect | Approved | 23577127 |
| DrugRepV_0804 | Dutasteride | Genito Urinary System and Sex Hormones | Prostatic hyperplasia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (66.475 %) | Approved | 27476412 |
| DrugRepV_0820 | Trospium Chloride | Genito Urinary System and Sex Hormones | Overactive bladder | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (57.11 %) | Approved | 27476412 |
| DrugRepV_0844 | Etonogestrel | Genito Urinary System and Sex Hormones | Contraception | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (57.965 %) | Approved | 27476412 |
| DrugRepV_0848 | Levonorgestrel | Genito Urinary System and Sex Hormones | Menopausal and postmenopausal disorders | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (58.52 %) | Approved, Investigational | 27476412 |
| DrugRepV_0855 | Raloxifene Hydrochloride | Genito Urinary System and Sex Hormones | Osteoporosis | Corticosteroid-induced bone loss | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (66.245 %) | Approved, Investigational | 27476412 |
| DrugRepV_0860 | Megestrol Acetate | Genito Urinary System and Sex Hormones | Anorexia | Cachexia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (61.545 %) | Approved, Investigational, Vet approved | 27476412 |
| DrugRepV_0899 | Progesterone | Genito Urinary System and Sex Hormones | Infertility | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.635 %) | Approved, Vet approved | 27476412 |
| DrugRepV_0902 | Danazol | Genito Urinary System and Sex Hormones | Endometriosis and fibrocystic breast disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (56.385 %) | Approved | 27476412 |
| DrugRepV_0903 | Estropipate | Genito Urinary System and Sex Hormones | Vaginal atrophy associated with the menopause | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (56.39 %) | Approved | 27476412 |
| DrugRepV_0908 | Acetohydroxamic Acid | Genito Urinary System and Sex Hormones | Bacterial infections | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.495 %) | Approved | 27476412 |
| DrugRepV_0921 | Oxybutynin Chloride | Genito Urinary System and Sex Hormones | Overactive bladder | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.105 %) | Approved, Investigational | 27476412 |
| DrugRepV_1013 | Vardenafil | Genito Urinary System and Sex Hormones | Erectile dysfunction | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.67 %) | Approved | 27476412 |
| DrugRepV_1032 | Alfuzosin | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.7 %) | Approved | 27476412 |
| DrugRepV_1054 | Dienogest | Genito Urinary System and Sex Hormones | Endometriosis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.265 %) | Approved | 27476412 |
| DrugRepV_1057 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.74 %) | Approved | 27476412 |
| DrugRepV_1063 | Estrone | Genito Urinary System and Sex Hormones | Perimenopausal and postmenopausal symptoms | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.96 %) | Approved | 27476412 |
| DrugRepV_1070 | Terazosin Hydrochloride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.235 %) | Approved | 27476412 |
| DrugRepV_1082 | Tiopronin | Genito Urinary System and Sex Hormones | Kidney stone | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.93 %) | Approved | 27476412 |
| DrugRepV_1107 | Finasteride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.37 %) | Approved | 27476412 |
| DrugRepV_1139 | Medroxyprogesterone Acetate | Genito Urinary System and Sex Hormones | Amenorrhea | Abnormal uterine bleeding | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.06 %) | Approved | 27476412 |
| DrugRepV_1158 | Testosterone Enanthate | Genito Urinary System and Sex Hormones | Primary hypogonadism | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.075 %) | Approved | 27476412 |
| DrugRepV_1183 | Flavoxate Hydrochloride | Genito Urinary System and Sex Hormones | Urinary syndromes | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.38 %) | Approved | 27476412 |
| DrugRepV_1214 | Sildenafil Citrate | Genito Urinary System and Sex Hormones | Erectile dysfunction | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.095 %) | Approved, Investigational | 27476412 |
| DrugRepV_1233 | Methylergonovine Maleate | Genito Urinary System and Sex Hormones | Postpartum hemorrhage | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.715 %) | Approved | 27476412 |
| DrugRepV_1239 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.36 %) | Approved | 27476412 |
| DrugRepV_1240 | Drospirenone | Genito Urinary System and Sex Hormones | Contraception | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.33 %) | Approved | 27476412 |
| DrugRepV_1245 | Terconazole | Genito Urinary System and Sex Hormones | Candidiasis (a yeast-like fungal infection) of the vulva and vagina | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.175 %) | Approved | 27476412 |
| DrugRepV_1255 | Alprostadil | Genito Urinary System and Sex Hormones | Palliative and erectile dysfunction | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.655 %) | Approved | 27476412 |
| DrugRepV_1306 | Dinoprostone | Genito Urinary System and Sex Hormones | Gestational trophoblastic disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.46 %) | Approved | 27476412 |
| DrugRepV_1403 | Tamsulosin Hydrochloride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.555 %) | Approved, Investigational | 27476412 |
| DrugRepV_1430 | Darifenacin Hydrobromide | Genito Urinary System and Sex Hormones | Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.55 %) | Approved | 27476412 |
| DrugRepV_1456 | Mifepristone | Genito Urinary System and Sex Hormones | Hypercortisolism | Nonpituitary cushing syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.56 %) | Approved | 27476412 |
| DrugRepV_1473 | Tolterodine Tartrate | Genito Urinary System and Sex Hormones | Overactive bladder | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (34.97 %) | Approved, Investigational | 27476412 |
| DrugRepV_1485 | Tadalafil | Genito Urinary System and Sex Hormones | Erectile dysfunction | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (40.655 %) | Approved | 27476412 |
| DrugRepV_1508 | Butoconazole Nitrate | Genito Urinary System and Sex Hormones | Vulvovaginal candidiasis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.275 %) | Approved | 27476412 |
| DrugRepV_1529 | Desogestrel | Genito Urinary System and Sex Hormones | Contraception | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (21.195 %) | Approved | 27476412 |
| DrugRepV_1677 | Phenazopyridine Hydrochloride | Genito Urinary System and Sex Hormones | Urinary tract infection | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1679 | Terazosin Hydrochloride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Hypertension | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1748 | Phenazopyridine Hydrochloride | Genito Urinary System and Sex Hormones | Urinary tract infection | Zika virus | MR766 | NA | Cell viability assay | Decrease (35.3 %) | Approved | 27571349 |
| DrugRepV_1750 | Terazosin Hydrochloride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Hypertension | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1819 | Phenazopyridine Hydrochloride | Genito Urinary System and Sex Hormones | Urinary tract infection | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Approved | 27571349 |
| DrugRepV_1821 | Terazosin Hydrochloride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Hypertension | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1975 | Terconazole | Genito Urinary System and Sex Hormones | Candidiasis (a yeast-like fungal infection) of the vulva and vagina | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2000 | Terconazole | Genito Urinary System and Sex Hormones | Candidiasis (a yeast-like fungal infection) of the vulva and vagina | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2021 | Clomiphene | Genito Urinary System and Sex Hormones | Cancer | Ebola virus | Zaire strain-pEBOV | NA | Firefly luciferase assay | Decrease (50 %) | Approved | 26585243 |
| DrugRepV_2028 | Iodoquinol | Genito Urinary System and Sex Hormones | Amoebiasis | Ebola virus | Zaire strain-pEBOV | NA | Firefly luciferase assay | Decrease (50 %) | Approved | 26585243 |
| DrugRepV_2050 | Oxybutynin | Genito Urinary System and Sex Hormones | Overactive bladder | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (80 %) | Approved, Investigational | 24841269 |
| DrugRepV_2182 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Ovulatory Dysfunction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (14.0147255 %) | Approved | 27742486 |
| DrugRepV_2184 | Estradiol Valerate | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (13.5411627 %) | Approved | 27742486 |
| DrugRepV_2205 | Tiopronin | Genito Urinary System and Sex Hormones | Kidney stone | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (8.70633878 %) | Approved | 27742486 |
| DrugRepV_2206 | Dutasteride | Genito Urinary System and Sex Hormones | Prostatic hyperplasia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (8.1427081 %) | Approved | 27742486 |
| DrugRepV_2207 | Ritodrine Hydrochloride | Genito Urinary System and Sex Hormones | Premature labour | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (8.00664706 %) | Approved, Investigational | 27742486 |
| DrugRepV_2275 | Drospirenone | Genito Urinary System and Sex Hormones | Contraception | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.94004334 %) | Approved | 27742486 |
| DrugRepV_2321 | Medroxyprogesterone Acetate | Genito Urinary System and Sex Hormones | Amenorrhea | Abnormal uterine bleeding | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.84716499 %) | Approved | 27742486 |
| DrugRepV_2334 | Finasteride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.57558611 %) | Approved | 27742486 |
| DrugRepV_2339 | Dienogest | Genito Urinary System and Sex Hormones | Endometriosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.3635241 %) | Approved | 27742486 |
| DrugRepV_2380 | Alfuzosin Hydrochloride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.46993265 %) | Approved | 27742486 |
| DrugRepV_2423 | Vardenafil | Genito Urinary System and Sex Hormones | Erectile dysfunction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.82388881 %) | Approved | 27742486 |
| DrugRepV_2437 | Silodosin | Genito Urinary System and Sex Hormones | Prostatic hyperplasia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.43672555 %) | Approved | 27742486 |
| DrugRepV_2464 | Megestrol Acetate | Genito Urinary System and Sex Hormones | Anorexia | Cachexia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.80324191 %) | Approved, Investigational, Vet approved | 27742486 |
| DrugRepV_2468 | Gestodene | Genito Urinary System and Sex Hormones | Progestogen hormonal contraceptive | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.76107127 %) | Investigational | 27742486 |
| DrugRepV_2473 | Levonorgestrel | Genito Urinary System and Sex Hormones | Menopausal and postmenopausal disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.60239654 %) | Approved, Investigational | 27742486 |
| DrugRepV_2482 | Butoconazole Nitrate | Genito Urinary System and Sex Hormones | Vulvovaginal candidiasis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.33976627 %) | Approved | 27742486 |
| DrugRepV_2556 | Oxybutynin Chloride | Genito Urinary System and Sex Hormones | Overactive bladder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.9623606 %) | Approved, Investigational | 27742486 |
| DrugRepV_2583 | Darifenacin Hydrobromide | Genito Urinary System and Sex Hormones | Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3801387 %) | Approved | 27742486 |
| DrugRepV_2588 | Oxybutynin | Genito Urinary System and Sex Hormones | Overactive bladder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.4048985 %) | Approved, Investigational | 27742486 |
| DrugRepV_2605 | Dapoxetine Hydrochloride | Genito Urinary System and Sex Hormones | Premature ejaculation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.6280168 %) | Approved | 27742486 |
| DrugRepV_2620 | Trospium Chloride | Genito Urinary System and Sex Hormones | Overactive bladder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7986713 %) | Approved | 27742486 |
| DrugRepV_2686 | Estriol | Genito Urinary System and Sex Hormones | Estrogen receptor | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.6485182 %) | Approved | 27742486 |
| DrugRepV_2687 | Fesoterodine Fumarate | Genito Urinary System and Sex Hormones | Overactive bladder syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.7220164 %) | Approved | 27742486 |
| DrugRepV_2698 | Tolterodine Tartrate | Genito Urinary System and Sex Hormones | Overactive bladder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9333711 %) | Approved, Investigational | 27742486 |
| DrugRepV_2725 | Sildenafil Citrate | Genito Urinary System and Sex Hormones | Erectile dysfunction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4050275 %) | Approved, Investigational | 27742486 |
| DrugRepV_2770 | Ulipristal | Genito Urinary System and Sex Hormones | Emergency contraceptive and uterine fibroids | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4064062 %) | Approved | 27742486 |
| DrugRepV_2772 | Progesterone | Genito Urinary System and Sex Hormones | Infertility | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4329417 %) | Approved, Vet approved | 27742486 |
| DrugRepV_2834 | Evista | Genito Urinary System and Sex Hormones | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.9810114 %) | Approved | 27742486 |
| DrugRepV_2835 | Tadalafil | Genito Urinary System and Sex Hormones | Erectile dysfunction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.0935254 %) | Approved | 27742486 |
| DrugRepV_2862 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.2174786 %) | Approved | 27742486 |
| DrugRepV_2865 | Solifenacin Succinate | Genito Urinary System and Sex Hormones | Overactive bladder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.2907234 %) | Approved | 27742486 |
| DrugRepV_2904 | Ethisterone | Genito Urinary System and Sex Hormones | Gynecological disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.2262254 %) | NA | 27742486 |
| DrugRepV_2909 | Estrone | Genito Urinary System and Sex Hormones | Perimenopausal and postmenopausal symptoms | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.6830838 %) | Approved | 27742486 |
| DrugRepV_3120 | Papaverine hydrochloride | Genito Urinary System and Sex Hormones | Impotence | Vasospasms | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (94.76 %) | Approved, Investigational | 23275491 |
| DrugRepV_3374 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Influenza virus | A/ WSN/1933 (H1N1) |  | High-throughput screening | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3854 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | Mayinga | NA | NA | Decrease (50 %) | Approved | 27490565 |
| DrugRepV_3857 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | Mayinga | NA | Renilla luciferase assay | Decrease (100 %) | Approved | 27490565 |
| DrugRepV_5403 | Clomiphene | Genito Urinary System and Sex Hormones | Female infertility | Lassa virus | Josiah | NA | Luciferase assay | Decrease (50 %) | Approved | 30700611 |
| DrugRepV_5404 | Clomiphene | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | Mayinga | NA | Luciferase assay | Decrease (50 %) | Approved | 30700611 |
| DrugRepV_5517 | Papaverine hydrochloride | Genito Urinary System and Sex Hormones | Impotence | Vasospasms | Lassa virus | NA | NA | Gaussia luciferase (Gluc) Glow assay | Decrease (50 %) | Approved, Investigational | 31786250 |
| DrugRepV_5525 | Papaverine | Genito Urinary System and Sex Hormones | Impotence | Vasospasms | Influenza virus | A/WSN/33 | | Plaque assay | Decrease (50 %) | Approved, Investigational | 31896588 |
| DrugRepV_5526 | Papaverine | Genito Urinary System and Sex Hormones | Impotence | Vasospasms | Influenza virus | B/Lee/40 | | Plaque assay | Decrease (50 %) | Approved, Investigational | 31896588 |
| DrugRepV_5527 | Papaverine | Genito Urinary System and Sex Hormones | Impotence | Vasospasms | Influenza virus | A/Udorn/72 | | Plaque assay | Decrease (50 %) | Approved, Investigational | 31896588 |
| DrugRepV_5528 | Papaverine | Genito Urinary System and Sex Hormones | Impotence | Vasospasms | Influenza virus | A/Equine/2/MIAMI/1/63 | | Plaque assay | Decrease (50 %) | Approved, Investigational | 31896588 |
| DrugRepV_5529 | Papaverine | Genito Urinary System and Sex Hormones | Impotence | Vasospasms | Influenza virus | A/PR/8/34 | | Plaque assay | Decrease (50 %) | Approved, Investigational | 31896588 |
| DrugRepV_5530 | Papaverine | Genito Urinary System and Sex Hormones | Impotence | Vasospasms | Influenza virus | B/MD/59 | | Plaque assay | Decrease (50 %) | Approved, Investigational | 31896588 |
| DrugRepV_5785 | Chlormadinone Acetate | Genito Urinary System and Sex Hormones | Atrophic vaginitis and estrogen deficiency | Dengue virus | Singapore isolates | | Plaque assay | Decrease (65 %) | NA | 25251726 |
| DrugRepV_7013 | Butoconazole Nitrate | Genito Urinary System and Sex Hormones | Vulvovaginal candidiasis | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved | 28814523 |
| DrugRepV_7564 | Bazedoxifene | Genito Urinary System and Sex Hormones | Postmenopausal osteoporosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7565 | Bazedoxifene | Genito Urinary System and Sex Hormones | Postmenopausal osteoporosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020 | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7573 | Alprostadil | Genito Urinary System and Sex Hormones | Palliative and erectile dysfunction | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7574 | Alprostadil | Genito Urinary System and Sex Hormones | Palliative and erectile dysfunction | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7591 | Hydroxyprogesterone | Genito Urinary System And Sex Hormones | Reduces the rate of recurrent preterm birth | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7592 | Hydroxyprogesterone | Genito Urinary System And Sex Hormones | Reduces the rate of recurrent preterm birth | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Experimental | 32438446 |
| DrugRepV_7665 | Diiodohydroxyquinoline | Genito Urinary System And Sex Hormones | Used in the treatment of amoebiasis. | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32473310 |
| DrugRepV_7669 | Diiodohydroxyquinoline | Genito Urinary System And Sex Hormones | Used in the treatment of amoebiasis. | SARS Coronavirus-2 | | NA | Viral load reduction assay | Decrease (90 %) | Approved | 32473310 |
| DrugRepV_7894 | Papaverine hydrochloride | Genito Urinary System and Sex Hormones | Impotence | Vasospasms | Lassa virus | NA | NA | GLuc assay | Decrease (50 %) | Approved, Investigational | 31786250 |
| DrugRepV_8182 | Drospirenone | Genito Urinary System and Sex Hormones | Contraception | Vaccinia virus | NA | | NA | Decrease (57.4 %) | Approved | 32708182 |